scFv Antibody Fragments Targeting HSPG2 for EMT Cancer Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer detection technologies, such as the CELLSEARCH system, rely on epithelial markers and miss rare circulating tumor cells with an invasive epithelial-to-mesenchymal transition (EMT) phenotype, leading to incomplete monitoring and characterization of cancer cells.

Innovation Solution

Development of an immune reagent comprising specific scFv antibody fragments that bind to HSPG2 (Perlecan), potentially linked as a diabody, conjugated with radionuclides or fluorescent agents for enhanced detection and treatment of cancer cells, including those with EMT phenotype.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current cancer detection technologies rely on epithelial markers, then detection of common cancer cells is achieved, but rare circulating tumor cells with EMT phenotype are missed

Engineering Contradiction:

Improvedetection accuracyVSAvoidability to detect diverse cancer cell phenotypes

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent changes the detection parameter from epithelial markers to HSPG2 (Perlecan) markers, which are expressed on cancer cells with EMT phenotype. This parameter change enables the detection system to identify rare circulating tumor cells that were previously undetectable using traditional epithelial markers, thereby improving both detection accuracy and phenotypic versatility.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses scFv antibody fragments as simplified copies of full antibodies, which bind specifically to HSPG2 on cancer cell surfaces. These antibody fragments serve as detectable copies that can be conjugated to detection agents, enabling sensitive and specific detection of cancer cells with EMT phenotype without requiring complex full antibody preparations.

Inventive Principle:

Principle #26Copying

2Reliability

If scFv antibody fragments are used to target HSPG2, then specific binding to cancer cells is achieved, but the complexity of reagent development increases

Engineering Contradiction:

Improvespecificity of cancer cell targetingVSAvoidreagent development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and utilizes only the variable regions (scFv fragments) of antibodies that bind to HSPG2, discarding the unnecessary constant regions and Fc portions. This extraction approach maintains the critical specificity function while simplifying the reagent structure, reducing development complexity and enabling easier conjugation to detection or therapeutic agents.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The scFv antibody fragments against HSPG2 serve multiple functions: they can be conjugated to detection agents for diagnostic purposes, to therapeutic agents for treatment, or used as basis for therapeutic antibodies. This multi-functionality reduces overall system complexity by using a single specific binding unit for diverse applications.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If conventional detection methods are used, then standard cancer monitoring is achieved, but incomplete monitoring of cancer cells occurs

Engineering Contradiction:

Improvemonitoring efficiencyVSAvoidinformation about EMT phenotype cancer cells

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent introduces HSPG2 (Perlecan) as an intermediary marker that mediates the detection of cancer cells with EMT phenotype. By targeting this specific protein expressed on the surface of invasive cancer cells, the detection system gains access to information about cancer cell invasion and metastasis potential that was previously inaccessible using traditional epithelial markers.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The immune reagent effectively targets and detects cancer cells, including those with EMT phenotype, improving the accuracy of cancer diagnosis and treatment by specifically binding to HSPG2, potentially increasing the detection of rare circulating tumor cells.

Implementation Method 1

an immune reagent comprising a first scFv antibody fragment (26-29 kDa) that specifically binds to membrane protein HSPG2 (Perlecan)

Methodology Applied

Scientific EffectAntibody binding:

Implementation Method 2

the immune reagent further comprises a second scFv antibody fragment operably linked to the first scFv antibody fragment (52-60 kDa) to form a diabody

Methodology Applied

Scientific EffectDiabody formation:

Data Source

PatentUS10166304B2Antibody fragments for detecting cancer and methods of use

Publication Date: 2019.01.01 REGENTS OF THE UNIVERSITY OF MINNESOTA

AI summary

The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.